SCHEMBL1722258

SCHEMBL1722258

CCSc1nc2cc(C(F)(F)F)ccc2c(C(C)C)c1C(=O)NCc1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 1/20 0.42
S1PR3 Q99500 2/20 0.42
CCR1 P32246 3/20 0.41
MLYCD O95822 1/20 0.40
MAPT P10636 1/20 0.40
MAOB P27338 1/20 0.40
PTGES O14684 1/20 0.39
GLS O94925 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE11A Q9HCR9 1/20 0.39
TACR1 P25103 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
ROCK2 O75116 2/20 0.38
MEN1 O00255 1/20 0.38
PLA2G1B P04054 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721614 0.90 DDR1 (0.44) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1721704 0.90 DDR1 (0.44) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1721281 0.90 DDR1 (0.44) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1721468 0.89 DDR1 (0.43) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1723128 0.88 DDR1 (0.42) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1722162 0.87 DDR1 (0.42) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1721263 0.84 DHODH (0.46) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1722435 0.83 MLYCD (0.48) CCR1MLYCDTACR1LMNAHPGD
SCHEMBL1722257 0.83 CCR1 (0.41) DDR1S1PR3CCR1MLYCDMAPT
SCHEMBL1721919 0.82 MAOB (0.41) S1PR3MAPTMAOBROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US claimed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US claimed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP claimed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO claimed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US claimed
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US disclosed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US disclosed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP disclosed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO disclosed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS KCNQ1, KCNQ2, KCNJ2 DDR1 4082/4885S1PR3 1478/4885CCR1 4805/4885
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators KCNQ1, KCNQ2, KCNJ2 DDR1 4082/4885S1PR3 1478/4885CCR1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.